Table 1.
Demographic and baseline clinical characteristics of patients
| Patient characteristic | ECOG 2 group | ECOG 0–1 group | Pb | ||||
|---|---|---|---|---|---|---|---|
| EP arm (n = 31) | PC arm (n = 40) | pa | EP arm (n = 64) | PC arm (n = 56) | pa | ||
| Age | 0.746 | 0.403 | 0.923 | ||||
| < 65, y | 23 (74.2%) | 31 (77.5%) | 51 (79.7%) | 41 (73.2%) | |||
| ≥ 65, y | 8 (25.8%) | 9 (22.5%) | 13 (20.3%) | 15 (26.8%) | |||
| Median | 56 | 58.5 | 59 | 56 | |||
| Range | 32–70 | 42–70 | 33–70 | 39–70 | |||
| Gender | 0.627 | 0.382 | 0.308 | ||||
| Male | 25 (80.6%) | 34 (85.0%) | 55 (85.9%) | 51 (91.1%) | |||
| Female | 6 (19.4%) | 6 (15.0%) | 9 (14.1%) | 5 (8.9%) | |||
| Weight loss | 0.276 | 0.878 | 0.674 | ||||
| < 5% | 17 (54.8%) | 27 (67.5%) | 42 (65.6%) | 36 (64.3%) | |||
| ≥ 5% | 14 (45.2%) | 13 (32.5%) | 22 (34.4%) | 20 (35.7%) | |||
| Smoking history | 0.887 | 0.644 | 0.457 | ||||
| Yes | 22 (71.0%) | 29 (72.5%) | 48 (75.0%) | 44 (78.6%) | |||
| No | 9 (29.0%) | 11 (27.5%) | 16 (25.0%) | 12 (21.4%) | |||
| Pathology | 0.912 | 0.500 | 0.082 | ||||
| Squamous | 23 (74.2%) | 31 (77.5%) | 42 (65.6%) | 31 (55.4%) | |||
| Adenocarcinoma | 6 (19.4%) | 6 (15.0%) | 14 (21.9%) | 15 (26.8%) | |||
| Other | 2 (6.5%) | 3 (7.5%) | 8 (12.5%) | 10 (17.9%) | |||
| AJCC stage | 0.747 | 0.566 | 0.326 | ||||
| IIIA | 6 (19.4%) | 9 (22.5%) | 19 (29.7%) | 14 (25.0%) | |||
| IIIB | 25 (80.6%) | 31 (77.5%) | 45 (70.3%) | 42 (75.0%) | |||
| Tumor stage | 0.612 | 0.392 | 0.662 | ||||
| T1 | 1 (3.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
| T2 | 19 (61.3%) | 22 (55.0%) | 41 (64.1%) | 33 (58.9%) | |||
| T3 | 7 (22.6%) | 13 (32.5%) | 17 (26.6%) | 13 (23.2%) | |||
| T4 | 4 (12.9%) | 5 (12.5%) | 6 (9.4%) | 10 (17.9%) | |||
| Nodal stage | 0.594 | 0.564 | 0.409 | ||||
| N2 | 9 (29.0%) | 14 (35.0%) | 23 (35.9%) | 23 (41.1%) | |||
| N3 | 22 (71.0%) | 26 (65.0%) | 41 (64.1%) | 33 (58.9%) | |||
| Pre-RT pulmonary function | |||||||
| FEV1 (L)c | 2.09 (1.08–4.38) | 1.99 (1.17–2.98) | 0.638 | 2.23 (1.15–4.05) | 2.07 (0.84–3.08) | 0.266 | 0.277 |
| FEV1 (% predicted) c | 65.1% (35.6–117.1%) | 65.5% (42.4–103.6%) | 0.656 | 70.3% (39.3–110.6%) | 63.1% (22.3–96.7%) | 0.133 | 0.607 |
Abbreviations: EP etoposide/cisplatin, PC paclitaxel/carboplatin, ECOG Eastern Cooperative Oncology Group, AJCC American Joint Committee on Cancer, FEV1 forced expiratory volume in 1 s
ap value for testing the null hypothesis of no difference between patients receiving EP and PC chemotherapy
bp value for testing the null hypothesis of no difference between ECOG 2 group and ECOG 0–1 group
c Median (range)